Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial

<p>Background: In sub-Saharan Africa, 20%-25% of people starting ART have severe immunosuppression; ~10% die within three months. In the recently-reported REALITY randomized trial, a broad enhanced anti-infection prophylaxis bundle reduced all-cause mortality versus cotrimoxazole alone; here,...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Post, F, Szubert, A, Prendergast, A, Johnston, V, Lyall, H, Fitzgerald, F, Musiime, V, Musoro, G, Chepkrorir, P, Agutu, C, Mallewa, J, Rajapakse, C, Wilkes, H, Hakim, J, Mugyenyi, P, Walker, A, Gibb, D, Pett, S, on behalf of the REALITY trial team
Médium:	Journal article
Vydáno:	Oxford University Press 2018

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial

Podobné jednotky